Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$VNDA Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.04 down -126.09% YoY • Reported revenue of $1.03M down -98.04% YoY • Vanda Pharmaceuticals Inc. is reiterating its 2026 total revenue guidance of $240 million to $290 million and expects to achieve various financial objectives across its product portfolio throughout the year.

Price since post

Full Details

Advertisement|Remove ads.